Actinium Pharmaceuticals Inc. [AMEX: ATNM] loss -9.67% or -0.04 points to close at $0.41 with a heavy trading volume of 17705246 shares. It opened the trading session at $0.42, the shares rose to $0.42 and dropped to $0.40, the range by which the price of stock traded the whole day. The daily chart for ATNM points out that the company has recorded 99.95% gains over the past six months. However, it is still -156.25% lower than its most recent low trading price.
If we look at the average trading volume of 10.36M shares, ATNM reached to a volume of 17705246 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Actinium Pharmaceuticals Inc. [ATNM]:
B. Riley FBR Inc. have made an estimate for Actinium Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 06, 2017. While these analysts kept the previous recommendation, ROTH Capital raised their target price to Buy. The new note on the price target was released on October 23, 2017, representing the official price target for Actinium Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $3, while Maxim Group analysts kept a Buy rating on ATNM stock.
The Average True Range (ATR) for Actinium Pharmaceuticals Inc. is set at 0.05 The Price to Book ratio for the last quarter was 13.55, with the Price to Cash per share for the same quarter was set at 0.03.
Trading performance analysis for ATNM stock
Actinium Pharmaceuticals Inc. [ATNM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 27.03. With this latest performance, ATNM shares gained by 126.08% in over the last four-week period, additionally plugging by 99.95% over the last 6 months – not to mention a rise of 66.60% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATNM stock in for the last two-week period is set at 71.05, with the RSI for the last a single of trading hit 69.64, and the three-weeks RSI is set at 70.95 for Actinium Pharmaceuticals Inc. [ATNM]. The present Moving Average for the last 50 days of trading for this stock 0.2243, while it was recorded at 0.4357 for the last single week of trading, and 0.2300 for the last 200 days.
Actinium Pharmaceuticals Inc. [ATNM]: A deeper dive into fundamental analysis
Return on Equity for this stock declined to -302.95, with Return on Assets sitting at -164.90.
Actinium Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.90 and a Current Ratio set at 1.90.
Actinium Pharmaceuticals Inc. [ATNM]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Actinium Pharmaceuticals Inc. posted -0.05/share EPS, while the average EPS was predicted by analysts to be reported at -0.06/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 16.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ATNM.
An analysis of insider ownership at Actinium Pharmaceuticals Inc. [ATNM]
There are presently around $5 million, or 7.90% of ATNM stock, in the hands of institutional investors. The top three institutional holders of ATNM stocks are: VANGUARD GROUP INC with ownership of 4,549,361, which is approximately -2.097% of the company’s market cap and around 0.90% of the total institutional ownership; BLACKROCK INC., holding 2,007,529 shares of the stock with an approximate value of $0.9 million in ATNM stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $0.53 million in ATNM stock with ownership of nearly 19.801% of the company’s market capitalization.
Positions in Actinium Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 14 institutional holders increased their position in Actinium Pharmaceuticals Inc. [AMEX:ATNM] by around 1,793,626 shares. Additionally, 16 investors decreased positions by around 4,580,690 shares, while 18 investors held positions by with 4,740,666 shares. The mentioned changes placed institutional holdings at 11,114,982 shares, according to the latest SEC report filing. ATNM stock had 5 new institutional investments in for a total of 402,978 shares, while 6 institutional investors sold positions of 859,945 shares during the same period.